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Objectives . The purpose of this study was to determine non .
invasively whether chest pain severity is predictive of the amount
of myocardium at risk and whether the response of pain during
thrombolysis is associated with myocardial salvage during acute
myocardial infarction .
Background. The perception of chest pain and response to
reperffision therapy during acute myocardial infarction may
provide important information for treatment benefit . Previous
studies have been limited by the inability to measure myocardium
at risk and myocardial salvage .
Methods. Sixty-two patients with acute myocardial infarction
received an injection of technetium-99m sestamibi before throm-
hol ;s and again at hospital discharge . Tomographic imaging was
performed 1 to 6 h later
. Myocardium at risk, infarct size and
absolute myocardial salvage were derived from these images using
previously described techniques and were expressed as a percent
of the left ventricle . Salvage index was calculated by dividing
myocardial salvage by the myocardium at risk . Chest pain sever-
ity was graded before thrombolysis as none, mild, moderate or
severe . Chest pain response during thrombolytic therapy was
graded as none, partial or completely resolved
.
It seems intuitively obvious to associate the severity of a
patient's symptoms during acute myocardial infarction and
his or her response to reperfusion therapy with the magni-
tude of myocardial necrosis . When symptoms resolve before
thrombolytic therapy, clinicians may be hesitant to proceed
with therapy because of a perceived increase in the risk/
benefit ratio. Herlitz et al . (1) found that in patients with
myocardial infarction who did not receive reperfusion ther-
apy, those with the most severe chest pain had a longer
duration of symptoms, developed higher peak levels of
From the Division of Cardiovascular Diseases and Internal Medicine,
Mayo Clinic and Mayo Foundation, Rochester, Minnesota . This study was
supported in part by a grant from DuPont Merck Radiopharmaceutical
Company, Billerica, Massachusetts .
Manuscript received December 14, 1992 ; revised manuscript received
March 12, 1993, accepted April 23, 1993 .
Address for correspand	: Timothy F . Christian, MD, Mayo Clinic,
W-16, 200 First Street, Southwest, Rochester, Minnesota 55905 .
01993 by the A:aerican College of Cardiology
1311
Results . There was no association between chest pain severity
and myocardium at risk, but there was a weak trend toward
greater myocardial salvage and salvage index (p = 0.09 and p =
112, respectively) for patients with more severe symptoms .
Patients without chest pain at the start of thrombolysis still
demonstrated significant salvage (11 ±: 11% of the left ventricle,
p = 0
.009). There was a significant association between chest pain
response to therapy and both myocardial salvage (p = 0.03) and
salvage index (p = 0 .01). By multivariate analysis, chest pain
severity and response of chest pain during thrombolysis were
significant independent predictors of myocardial salvage, salvage
index and infarct size . Thrombolysis was most effective in the 20
patients (32%) with moderate or severe chest pain and complete
resolution of symptoms during thrombolysis (salvagwa of 79% to
89% of the area at risk) . In the remaining 32 patients with chest
pain, salvage of the area at risk was only 32%
.
Conclusions. These findings suggest that the assessment of
chest pain before and after thrombolytic therapy is a readily
available, useful indicator of the efficacy of the therapy .
(J Am Coll Cardiol 1)93,22:1311-6)
cardiac serum enzymes and were more likely to develop Q
wave infarction than were patients with less severe symp-
toms. Several reports (2-4) have shown that a patient's
subjective response to thrombolytic therapy, particularly the
complete resolution of pain, is significantly associated with
patency of the infarct-related artery, but the confidence
limits have been wide . None of these studies analyzed the
initial severity of symptoms or correlated symptonis with
myocardium at risk and myocardial salvage .
Myocardium at risk, infarct size and myocardial salvage
have been measured with tomographic technetium-99m
(99mTc) sestamibi imaging in both animal studies of coronary
occlusion and reperfusion (5-7) and clinical studies of myo-
cardial infarction (8-12) . The purpose of this study was to
determine the relation between chest pain severity during
acute myocardial infarction and chest pain response during
intravenous thrombolytic therapy with myocardium at risk
and myocardial salvage .
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Methods
he study group was selected from a consecutive series
of 207 patients enrolled in a prospective study of "mTc
sestamibi in acute myocardial infarction who met the follow-
ing inclusion criteria: 1) chest pain '30 min in duration
;
2) ST segment elevation on the 12-lead electrocardiogram
(ECG) X0
.I mV in at least two contiguous eads in the same
vascular territory (anterior, leads V1 to V4 ; inferior, leads 11,
III and aVF; lateral, leads I and aVL' ; 3) intravenous
thrombolytic therapy infusion initiated X12 h from the onset
of chest pain ; 4) men > IS years of age and postmenopausal
women. Of 70 patients who met these criteria, g were
excluded : 7 because of evidence of previous myocardial
infarction and 1 with unsuccessful thrombolysis but success-
ful early rescue angioplasty . Therefore, 62 patients formed
the study group. Eighteen patients with recurrent ischemia
underwent emergency coronary angiography and subse-
quent coronary angioplasty (13)
. There was no difference in
any clinical or chest pain characteristic between these pa-
tients and the remainder of the study group . None of these
patients had recurrent myocardial infarction during the hos-
pital period
.
Tiwombolytic therapy. Intravenous thrombolysis was
performed using previously described methods with either
recombinant tissue-type plasminogen activator (60 patients)
or streptokinase (2 patients) (14,15). The time to therapy was
measured from the onset of chest pain to the initiation of
thrombolytic therapy . Morphine sulfate and beta-adrenergic
receptor blockade were used at the discretion of the attend-
ing cardiologist .
Subjective eat of chest Pain. Assessment of chest
symptoms was recorded by the physician responsible for
initiating thrombolysis and was reviewed retrospectively by
a single observer (M .R.H.) . Chest pain severity was scored
just before reperfusion, as outlined by Kircher et al . (4),
using a scale from 0 to 10, where 0 = no pain, 10 = the most
severe pain. Severity of chest pain was then classified as
none-that is, previously present but resolved (0)
; mild (i to
4)
; moderate (5 to 7) or severe (8 to 10) at the time of the
initiation of thrombolytic therapy . The response of chest
pain to therapy was graded as none, partial or completely
resolved at the end of the thrombolytic infusion by physi-
cians unaware of the results of the "mTc sestamibi images .
Stuttering pain before thrombolysis was defined as at least
one episode of chest pain within 24 h of presentation that
partially or completely resolved but recurred . No analysis of
recurrent pain during thrombolytic infusion was performed,
t of um at risk and final
. All patients received an injection of 9 Tc
sestamibi; (20 to 30 mCi) before thrombolytic therapy. Be-
cause of the minimal redistribution of this radionuclide agent
when in acted at rest, tomographic imaging was performed 1
to 6 h later, after thrombolysis, to determine the initial
perfusion pattern. A second injection and image acquisition
were performed at hospital discharge 7 ± 1
.5 days from
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admission . Technetium-99m sestamibi images were acquired
and processed by a nuclear technologist without knowledge
of the patient's symptoms or clinical course with use of a
previously described technique (8)
.
The left ventricular perfusion defect was quantitated
using a previously described threshold method (8,10,16) .
The extent of the defect on the image acquired I to 6 h after
thrombolysis reflects myocardium at risk, and the extent of
the defect on the predischarge image reflects final infarct
size. Absolute myocardial salvage was defined as (myocar-
dium at risk - final infarct size) . The salvage index (i.e ., the
proportion of myocardium at risk that is salvaged) is equal to
(absolute myocardial salvagelniyocardium at risk)
. When the
value of myocardial salvage was a negative number, the
salvage index was set equal to zero .
Statistical analysis . Data are presented as mean value ®1
SD. A one-factor analysis of variance (ANOVA) was used to
compare nominal variables, such as chest pain severity and
response, with variables of myocardium at risk, myocardial
salvage and infarct size . When the data were not normally
distributed, a Kruskal-Wallis test was used, and p values
were adjusted for infarct location (anterior vs . inferior or
lateral) . Simple linear regression was used to compare con-
tinuous variables, such as age and time to thrombolysis, with
estimates of salvage and infarct size. Chi-square contingency
table analysis or an unpaired r test was used to compare
clinical variables. We entered chest pain severity with all
other clinical variables as covariates in ANOVA models,
with the continuous variables of myocardial salvage, salvage
index and infarct size as dependent variables . Clinical vari-
ables were eliminated in a stepwise fashion based on the
lowest f values until all remaining variables in the model had
p values a 0
.05 .
Results
All patients received intravenous heparin and nitroglyc-
erin in the emergency room . Beta-adrenergic blocking agents
were given to 51 patients (82%) on presentation . Only 13% of
patients were taking antianginal medications before presen-
tation . Seven patients (11%) had diabetes mellitus, 24 (39%)
had a previous history of angina and 10 (16%) had a
stuttering course of chest pain before presentation . Patients
with anterior infarction were more likely to have complete
resolution of symptoms than were patients with an inferior
or lateral infarction (Tables I and 2) .
Severity of chest pain . The amount of myocardium at risk
was not significantly associated with chest pain severity
(Table 1) . The patient group that received a'9'Tc sestamibi
injection after their chest pain had resolved but before
thrombolysis had a substantial amount of myocardium at
risk (24 ± 19% of the left ventricle) despite a preponderance
of patients with inferior infarction . There was a weak asso-
ciation (p = 0.07) between final infarct size and chest pain
severity due primarily to the greater infarct size in the
subgroup of patients with mild chest pain . Seven of 11
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Table 1
. Chest Pain Severity at Presentation
Values presented are mean value ± SD or number (%)
. ANVOVA = two-factor analysis of variance with infarct location as one factor and the particular
radionuclide measure the other factor ; Ant = anterior infarction ; lnf = inferior infarction
; Lat = lateral infarction
; %LV = % of the left ventricle .
patients in this subgroup had anterior infarction, and adjust-
ment for infarct location weakened this association . There
was no significant difference in the number of patients who
received morphine or beta blockers and the severity of chest
symptoms. Myocardial salvage and salvage index tended to
be higher in patients with severe symptoms, but this trend
did not reach statistical significance, even after adjustment
for infarct location . In patients without chest pain at the
initiation of thrombolytic therapy, myocardial salvage (11
11% of the left ventricle) and salvage index (0 .49 ± 0.35 of
the area at risk) were comparable to those of patients with
chest pain . Figure 1 shows an example of myocardial salvage
by 99mTc sestamibi in a patient without chest pain at the time
of thrombolysis .
Response of chest pain to thrombolytic therapy . There
was no significant difference in the extent of myocardium at
risk between patients with complete, partial or no response
of chest pain during thrombolytic therapy (Table 2) . Infarct
size, myocardial salvage and salvage index were significantly
associated with the patient's subjective chest pain response
to thrombolytic therapy (Tables 2 and 3, Fig . 2 and 3) .
Patients with complete resolution of symptoms demon-
strated the greatest degree of salvage and the smallest final
infarct size . There was no aswciation between the adminis-
tration of morphine or beta-blockers and chest pain response
during thrombolysis .
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The response of chest pain to thrombolysis was most
helpful in predicting outcome when considered in conjunc-
tion with chest pain severity at presentation (Table 3) . The
20 patients with moderate or severe chest pain and complete
resolution of pain during thrombolysis had salvage of 79% to
89% of the area at risk . Conversely, all other patients with
symptoms (32 patients with mild chest pain or partial or no
response) demonstrated salvage of 32% of the area at risk .
Other univariate predictors of infarct size and myocardial
salvage. There was no significant difference between pa-
tients with and without previous angina, stuttering chest
pain, previous use of antianginal medications or other clini-
cal variables when the data were analyzed for absolute
myocardial salvage, salvage index or final infarct size .
Multivariate analysis. Multivariable models were con-
structed to predict absolute myocardial salvage, salvage
index and final infarct size (Table 4) . All clinical variables
were considered for inclusion in the models (gender, diabe-
tes, previous angina, stuttering chest pain, antianginal med-
ications, chest pain severity, chest pain response, age,
infarct location and time to thrombolysis) . Infarct location
was highly predictive of myocardial salvage and infarct size,
but this association was not significant when the extent of
myocardium at risk was adjusted for by use of the salvage
index. Only chest pain severity and response to thrombolytic
therapy were independently associated with all three mea-
*Excluding 10 patients without chest pain . tKruskal-Wallis test
. Values presented are mean value ± SD or number (%)
. Abbreviations as in Table I
.
Chest Pain Severity
p Value
p Value Adjusted
for infarct
Location
(ANOVA)
None
(n = 10)
Mild
(n = 11)
Moderate
(n = 27)
Severe
(n = 14)
InfiAnt/Lat
2/8/0 7/410
9/16/2 7/7/0
0.15
Morphine before thrombolysis
4(40%) 505%) 15 (56%)
11 (79%) 0 .22
Time to thrombolysis (h) 3 .6 ± 1 .8 3 .6 ± 1 .4
2 .7 ± 1 .8 3 .1 ± 1 .7
0 .35
Myocardium at risk (%LV)
24 ± 19 37 ± 20
30 ± 19 35 ± 19 0 .43
0.96
Infarct size (%LV)
13 ± 10 26 ± 19 13 ± 15
I1 ± 13 0 .07
0.14
Salvage (%LV) II ±11
II ± 13 17 ± 19
23 ± 19 0 .24
0.09
Salvage index 0 .49 ± 0.35 0.33 ± 0 .34
0.54 ± 0 .41 0.65 ± 0.33
0 .20 0.12
Table 2 . Chest Pain Response to Thrombolysis
Chest Pain Response
p Value
p Value Adjusted
for infarct
Location
(ANOVAI
None*
(n = 4)
Partial
(n = 20)
Complete
(n = 28)
Inf/Ant/Lat 3/1/0 411511
16/1111 0 .02
Morphine during thrombolysis 20090)
13 (65%) 14 (50%) 0 .57
Time to thrombolysis (h) 3 .7 ± 0 .9
3.0 ± 1 .9 2 .9 ± 1 .6
0 .68
Myocardium at risk (%LV)
33 ± 23 30 ± 17
34 ± 21 0 .73
0 .16
Infarct size (%LV) 29 ± 25 18 ± 12
11 ± 17 0 .08
0 .03
Salvage (96LV) 5 ± 2 12 ± 16
23 ± 20 0 .03t
0 .04
Salvage index 0.26 ± 0 .23 0 .36 ± 0
.35 0.68 ± 0 . 1 7 0-01f
0 .
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cures of outcome (myocardial salvage, salvage index and
final infarct size) .
Discussion
There is a clear discrepancy in mortality between patients
who are eligible and receive thrombolytic therapy and those
not meeting eligibility requirements (17) . Consequently, it is
important to clearly define eligibility criteria . The resolution
of chest pain before initiation of thrombolytic therapy may
dissuade some clinicians from proceeding with such therapy
because there is a small but tangible risk of intracerebral
hemorrhage (18) . It is also important that the clinician in
smaller rural hospitals with limited resources he able to
judge the success or failure of reperfusion therapy to guide
further management . The subjective assessment of reperfu-
Sion therapy may become more important with the advent of
thrombolytic therapy given in the field or en route to the
hospital.
There was no significant association between the degree
Table 3. Relation of Chest Pain Severity and Response to
Myocardial Salvage Index*
cbest Paain Severity
Chest Pain Response
	
Mild Moderate
Severe
None
-(0)
005(t) 0,46(3)
NOW
053(3) 0 .?3 (13)
0.36(4)
Completely resolved 0,25(8)
089(13)
0,79(7)
"Salvage index is the proportion of myocardium
at rsk s alvaged . a s
measured by technetium-99m sestearnibi Values presented are mean value
(number of patients).
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Flgure 1 . Technetium-99m (""cc) sestamibi short-axis
(SA) views at midventricle (MID) (top) and base (bot-
tom) in a patient with anterior ST elevation but whose
chest pain had resolved before thrombolysis . Left,
"Te sestamibi injected before thrombolysis and im-
ages acquired subsequently show an anteroseptal de-
fect comprising 5 .591v of the left ventricle . Right, images
Ooquwed on day 7 show that the perfusion defect size
has decreased to 281% of the left ventricle after throm-
bolysis . Myocardial salvage for this patient is 27% of
the left ventricle, and the salvage index is 0 .49. ACUTE
w image acWiwed I to 6 h after thrombolysis : DISCH
image acquired at hospital discharge .
of chest pain severity and the amount of myocardium at risk,
suggesting that the potential magnitude of infarction cannot
be assessed by thc patient's symptoms . The substantial
amount of myocardium at risk and subsequent myocardial
salvage in patients whose chest pain resolved before throm-
hollysis, despite a preponderance of inferior infarction in this
subgroup, indicates that pahc-nts .with ST elevation but no
further pain should still he given thrombolytic therapy
. The
finding of benefit in the absence of symptoms is in agreement
with a preliminary report from the Thrombolysis in Myocar-
dial Infarction (TIMI) investigators (19) . Cox et al . (19)
found that patients with chest pain that resolved before
thrombolysis had a significantly greater ejection fraction at 6
weeks than did those with pain at the time of thrombolysis .
Figure 2. Association between the subjective assessment of chest
pain response to intravenous thrombolysis and myocardial salvage
(Acute perfusion defect size - Discharge perfusion defect size) .
%L V = percent of left ventricle .
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Figure 3. Association of the subjective assessment of chest pain
response to thrombolysis and the salvage index Wyocardial sml
vagOldyocarditurr at risk), where a value of I .0 represents complete
salvage .
However, they did not have a measure of Inyoemdiwn at
risk and, consequently, could not exclude the possibility that
these patients would have had a small infarct without thimu-
bolytic therapy (19) .
Previous studies addressing the subjective response to
thrombolytic therapy (2-4) have not been able to quantitate
myocardium at risk (or, consequently, myocardial salvage)
Technetium-99m sestarnibi is taken up in proportion to blood
flow at linear rates when injected at rest (20), is entrapped in
the mitochondria of myocytes (21) and dernonstiates mini-
mal redistribution when injected at rest (20,22) . Conse-
quently, it can be injected before thrombolysis, and ton o .
graphic imaging can be performed I to 6 h later . after
thrombolytic therapy, and still reflect myocardial perfusion
before therapy, even in the presence of reperfusion flow
(6,7) .
A second injection and image acquisition at hospital
discharge provide an accurate measure of infarct size
(11,23,24) . Because ""Tc sestarnibi requires intact mito-
chondria) function and sarcolemmal membrane integrity for
uptake, it is primarily a viability rather than a flow tracer in
this setting (25) . Therefore, myocardial salvage Lan be
calculated by the change in perfusion defect size . Clearly .
myocardial salvage cannot occur without patency of the
infarct-related artery . This finding was evident from a pre-
vious study (10) from this laboratory, in which patients with
persistent occlusion of the infarct-related artery demon-
strated a change in perfusion defect size before and after
reperfusion therapy (myocardial salvage) of 0 ± 2% of the
Table 4. Independent Predictors of Myocardial Salvage, Salvage Index and Infarct Size
.
R1 of the model 0 .48 . tR 1 of the model = 0.31 . W of the model = 0.32.
CHRIS I IAN ET AL .
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left ventricle compared with 17 a: 14% of the left ventricle in
patients with patent infarct-related arteries
. However, pa-
rcno.;y can occur in the absence of myocardial salvage . Thus,
salvage should be a more useful end point than patency .
I he subjective response of chest pain to thrombolysis
was significantly associated with myocardial salvage
. Com-
plete relief was associated with the greatest degree of
salvage. This finding occurred in 45% of patients. Both the
response of chest pain to thrombolytic therapy and the
severity of chest pain at the initiation of thrombolysis
provided independent information with regard to salvage and
infarct size . Patients with moderate or severe symptoms
with complete resolution salvaged 79% to 89% of the area at
risk these subjective variables were relatively weak predic-
tors of myocardial salvage but were more predictive than the
elapsed time to thrombolysis from the onset of symptoms .
Ibis study is also in agreement with those of Califf et al .
(2) and Kircher et al, (4), who found a significant, though
weak, association between subjective variables of chest pain
and infarct artery recanalization . 'This study differs from
those in two important aspects . First, the severity of chest
pain, a variable that provided significant additional informa-
tion in our study, was not analyzed by either previous study .
Second, we used myocardial salvage rather than infarct-
related artery patency as the end point . Recanalization of a
coronary occlusion may not produce myocardial sallvaf°,
even when achieved early, if metabolic demand is high, area
at risk large and collateral flow negligible (26-28) .
Study limitations . The design of this study was to deter-
mine which variables could predict myocardial salvage
solely on the basis of the information that a clinician could
obtain from the patient by taking a history . `The controversial
issue of the resolution of ECG ST' segment changes (2-4,29)
was specifically avoided . Continuous quantitative S F seg-
ment monitoring may be necessary to draw accurate conclu-
sions with regard to the success of reperfusion therapy
(29,30) . ,Such measurements were not available in this group
of patients . Furthermore, angiography was not available for
all patients . although 99'"Tc sestamibi imaging has been
shown to be a reliable surrogate for assessing arterial pa-
tency (8,10,12,31) . Finally, the assessment of chest pain
severity is frequently problematic in acutely ill patients, and
the impact of recurrent chest pain during the thrombolytic
infusion is unknown .
Despite these limitations, this study suggests that reas-
sessment of chest pain before and during thrombolysis is a
Myocardial Salvage* Salvage Indext
Infarct Sizet
Variable
F p
Value Value
F
Value
p
Valor
F
Value
p
Value
Infarct location 25 .8 < 0 .0001
- - 4.6 0 .04
Chest pain severity 6 .2 0 .001 4 .2
0 .009 4.2 0 .009
thcst pain response 1.9 0.0009
9.5 00003 67 0002
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useful, readily available indicator of the efficacy of reperfu-
Sion therapy .
We thank Kay Knox for preparation of the manuscript .
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